Abstract:Key PointsTumour necrosis factor-related apoptosis-inducing ligand (TRAIL) is a molecule belonging to the tumour necrosis factor (TNF) superfamily. In humans, two TRAIL receptors (TRAIL-R1 and TRAIL-R2) and in mice one receptor (mTRAIL-R) can signal apoptosis upon binding of TRAIL.Induction of apoptosis is enabled through recruitment of the death-inducing signalling complex (DISC). This complex leads to activation of a caspase cascade.TRAIL–TRAIL-R binding can also induce non-apoptotic signalling including via activation of nuclear factor-κB (NF-κB), p38, ERK, SRC and RAC1.Mice deficient in TRAIL or mTRAIL-R are more susceptible to various cancers whereas conditional deletion of mTRAIL-R in Kras- driven cancers ameliorates disease progression. TRAIL–TRAIL-R blockade might therefore be a therapeutic option for patients with KRAS-mutated cancers.TRAIL–TRAIL-R interaction on myeloid-derived suppressor cells in the tumour microenvironment can limit their lifespan and thereby tip the balance towards an antitumour immune environment. Hence, patients with an immunosuppressive cancer microenvironment might benefit from TRAIL-R agonistic therapy.Clinical trials testing an untagged form of recombinant TRAIL, agonistic TRAIL-R1 or TRAIL-R2-specific antibodies or antibody derivatives with higher crosslinking capacity have not led to anticipated therapeutic benefit.Preclinical approaches using therapeutic combinations comprising optimized TRAIL-R agonists and recently discovered powerful apoptosis sensitizers are, however, promising. Therefore, such novel pro-apoptotic combination therapies should be tested in clinical trials.Several drugs, some of which have been approved by the US Food and Drug Administration, induce extrinsic apoptosis through autocrine engagement of the TRAIL–TRAIL-R pathway. Therefore, expression of TRAIL apoptosis pathway components, as well as lack of expression of inhibitors thereof, might be useful for patient selection in clinical trials testing the efficacy of such drugs.

Proscillaridin A Sensitizes Human Colon Cancer Cells to TRAIL-Induced Cell Death

Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms.

17-hydroxy wortmannin restores TRAIL's response by ameliorating increased beclin 1 level and autophagy function in TRAIL-resistant colon cancer cells.

Overcoming Acquired TRAIL Resistance in Human Colon Cancer by Proteasome Inhibitor Bortezomib

Changes and Significance of Fas and Cflip in Apoptosis of Human Rhabdomyosarcoma Cells Induced by Combination of TRAIL and Cisplatin

Aplysin Sensitizes Cancer Cells to TRAIL by Suppressing P38 MAPK/Survivin Pathway

Triptolide sensitizes pancreatic cancer cells to TRAIL-induced activation of the death receptor pathway

Strophanthidin Induces Apoptosis of Human Lung Adenocarcinoma Cells by Promoting TRAIL-DR5 Signaling

[Action of Apoptosis-Induced Ligand Gene in Relation to Tumor Necrosis Factor on Human Colon Cancer Cell Line HT29].

Tunicamycin enhances human colon cancer cells to TRAIL-induced apoptosis by JNK-CHOP-mediated DR5 upregulation and the inhibition of the EGFR pathway

Novel Insights into the Synergistic Interaction of a Thioredoxin Reductase Inhibitor and TRAIL: the Activation of the ASK1-ERK-Sp1 Pathway

2-Tellurium-bridged Β-Cyclodextrin, a Thioredoxin Reductase Inhibitor, Sensitizes Human Breast Cancer Cells to TRAIL-induced Apoptosis Through DR5 Induction and NF-κB Suppression.

Shikonin sensitizes A549 cells to TRAIL-induced apoptosis through the JNK, STAT3 and AKT pathways

Cisplatin enhances the antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand gene therapy via recruitment of the mitochondria-dependent death signaling pathway

Enhanced extrinsic apoptosis of therapy-induced senescent cancer cells using a death receptor 5 (DR5) selective agonist

Proscillaridin A Induces Mitochondrial Damage and Autophagy in Pancreatic Cancer and Reduces the Stability of SMAD4 in Panc-1 Cells

Marine Actinomycetes-Derived Secondary Metabolites Overcome TRAIL-Resistance via the Intrinsic Pathway through Downregulation of Survivin and XIAP

Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy

N-Acetyl-Glucosamine Sensitizes Non-Small Cell Lung Cancer Cells to TRAIL-Induced Apoptosis by Activating Death Receptor 5

Paclitaxel Enhances Tumoricidal Potential of TRAIL Via Inhibition of MAPK in Resistant Gastric Cancer Cells.

Enhancing TRAIL-induced apoptosis by Bcl-XL siRNA